title: Treatment of Churg-Strauss syndrome with high-dose intravenous immunoglobulin.
abstract: BACKGROUND
  In some patients with Churg-Strauss syndrome (CSS), especially those with myocardial or neural involvement, conventional treatment with corticosteroids with or without cyclophosphamide is not effective.
  
  
  OBJECTIVE
  To examine the effects of intravenous high-dose immunoglobulin (IVIG) in patients with CSS who showed poor responsiveness to conventional treatment.
  
  
  METHODS
  We consecutively selected patients with CSS who showed any organ involvement despite corticosteroid treatment with or without cyclophosphamide. The diagnosis was based on the classification criteria of the American College of Rheumatology. IVIG therapy was performed with a dose of 400 mg/kg of immunoglobulin daily for 5 days. Neuropathy was evaluated with the manual muscle strength test and by the skin temperature of affected sites. Cardiac function was examined with ejection fraction by echocardiography and 2 imaging tests of myocardium (iodine 123 metaiodobenzylguanidine and thallium 201).
  
  
  RESULTS
  The manual muscle strength test results were improved, and the skin temperature of both hands and legs was increased by IVIG therapy. In 5 patients with heart failure, the mean +/- SD ejection fraction of the left ventricle increased from 35.2% +/- 13.9% to 61.0% +/- 10.1% (P < .02). The uptake of iodine 123 metaiodobenzylguanidine of the myocardium increased, indicating that the myocardial viability was improved. The thallium 201 images revealed the presence of perfusion defects, which were improved by IVIG therapy.
  
  
  CONCLUSIONS
  Patients with CSS who are resistant to corticosteroid treatment with or without cyclophosphamide may be treated effectively with IVIG therapy.
authors.affiliation: Clinical Research Center of Sagamihara National Hospital, Sagamihara, Kanagawa-ken, Japan. n-tsurikisawa@sagamihara-hosp.gr.jp
authors.forename: Naomi
authors.initials: N
authors.lastname: Tsurikisawa
authors.forename: Masami
authors.initials: M
authors.lastname: Taniguchi
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Saito
authors.forename: Hideo
authors.initials: H
authors.lastname: Himeno
authors.forename: Akihiko
authors.initials: A
authors.lastname: Ishibashi
authors.forename: Shunsuke
authors.initials: S
authors.lastname: Suzuki
authors.forename: Kazuo
authors.initials: K
authors.lastname: Akiyama
mesh_terms: D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000328:Adult; D000368:Aged; D015267:Churg-Strauss Syndrome / Q000150:complications / Q000188:drug therapy*; D003520:Cyclophosphamide / Q000627:therapeutic use; D005260:Female; D006333:Heart Failure / Q000150:complications / Q000188:drug therapy; D006801:Humans; D016756:Immunoglobulins, Intravenous / Q000008:administration & dosage / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010523:Peripheral Nervous System Diseases / Q000150:complications / Q000188:drug therapy; D016896:Treatment Outcome
chemical_list: D000305:Adrenal Cortex Hormones; D016756:Immunoglobulins, Intravenous; D003520:Cyclophosphamide